Olanzapine and acute urinary retention in two geriatric patients

Alexopoulos, 2004, Using antipsychotic agents in older patients, J Clin Psychiatry, 65, 5 Rapoport, 2005, Anti-psychotic use in the elderly: Shifting trends and increasing costs, Int J Geriatric Psychiatry, 20, 749, 10.1002/gps.1358 Richelson, 1999, Receptor pharmacology of neuroleptics: Relation to clinical effects, J Clin Psychiatry, 60, 5 Rosack, 2005, FDA orders new warning on atypical antipsychotics, Psychiatric News, 40, 1 Chew, 2006, A model of anticholinergic activity of atypical antipsychotic medications, Schizophrenia Res, 88, 63, 10.1016/j.schres.2006.07.011 Lepor, 2005, Managing and preventing acute urinary retention, Rev Urol, 7, S26 Dmochowski, 2005, Bladder outlet obstruction: Etiology and evaluation, Rev Urol, 7, S3 Roehrborn, 1999, Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia, Urology, 53, 473, 10.1016/S0090-4295(98)00654-2 Katzung, 2001, 98 Olanzapine [drug safety information sheet] [FDA Web site]. Semaan, 2006, Dose-dependent urinary retention following olanzapine administration, Ann Pharmacother, 40, 1693, 10.1345/aph.1G697 Vera, 2001, Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats, BMC Pharmacol, 1, 4, 10.1186/1471-2210-1-4 Donepezil [drug safety information sheet] [FDA Web site] Sakakibara, 2005, Preliminary communication: Urodynamic assessment of donepezil hydrochloride in patients with Alzheimer's disease, Neurourol Urodyn, 24, 273, 10.1002/nau.20102 Naranjo, 1981, A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther, 30, 239, 10.1038/clpt.1981.154 Reynard, 2005, 98 Rose BD. Diagnosis of urinary tract obstruction and hydronephrosis. UpToDate. Teuvo T, et al. Benign prostatic hyperplasia. National Guideline Clearinghouse, 2006. Available at: O'Leary, 2001, Redefining alpha blocker selection in benign prostatic hyperplasia to improve safety and tolerability: Focus on tamsulosin, Clin Geriatr, 3 Djavan, 1999, A meta-analysis on the efficacy and tolerability of alphal-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction, Eur Urol, 36, 1, 10.1159/000019919 McConnell, 1998, The effect of finastcridc on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia, N Engl J Med, 338, 557, 10.1056/NEJM199802263380901 Roehrborn C, McConnell J, Barry M, et al, for the American Urological Association. 2006 American Urological Association guidelines for treatment of BPH [AUA Web site]. Available at: McConnell, 2003, The long-term effect of doxazosin, finasteride, and combination therapy on thc clinical progression of benign prostatic hyperplasia, N Engl J Med, 349, 2387, 10.1056/NEJMoa030656 Wessells, 2003, Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia, Urology, 61, 579, 10.1016/S0090-4295(02)02401-9 Proscar [drug safety information sheet] [FDA Web site]. Available at: Cunningham G, Kadmon D. Surgical and other invasive therapy of benign prostatic hyperplasia. UpToDate. Available at: Gonzalez, 2003, How do transurethral needle ablation of the prostate and transurethral microwave thermotherapy compare with transurethral prostatectomy?, Curr Urol Rep, 4, 297, 10.1007/s11934-003-0088-x Roehrborn, 1998, Transurethral needle ablation for benign prostatic hyper- plasia: 12-Month results of a prospective, multicenter US study, Urology, 51, 415, 10.1016/S0090-4295(97)00682-1 Chew, 2006, A model of anticholinergic activity of atypical antipsychotic medications, Schizophr Res, 88, 63, 10.1016/j.schres.2006.07.011 Herrmann, 2005, Do atypical antipsychotics cause stroke?, CNS Drugs, 19, 91, 10.2165/00023210-200519020-00001 Schneider, 2005, Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials, JAMA, 294, 1934, 10.1001/jama.294.15.1934 Herrmann, 2006, Atypical antipsychotics for neuropsychiatric symptoms of dementia: Malignant or maligned?, Drug Saf, 29, 833, 10.2165/00002018-200629100-00002 Sink, 2005, Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence, JAMA, 293, 596, 10.1001/jama.293.5.596 Schneider, 2006, Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease, N Engl J Med, 355, 1525, 10.1056/NEJMoa061240 Beier, 2007, Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly, Am J Health Syst Pharm, 64, S9, 10.2146/ajhp060594 Livingston, 2005, Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia, Am J Psychiatry, 162, 1996, 10.1176/appi.ajp.162.11.1996 Ayalon, 2006, Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: A systematic review, Arch Intern Med, 166, 2182, 10.1001/archinte.166.20.2182